Semin Vasc Med 2003; 03(2): 199-204
DOI: 10.1055/s-2003-40678
Copyright © 2003 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

rFVIIai in Acute Coronary Syndromes

Brit Binow Sorensen1 , Ulla Hedner2 , Elisabeth Erhardtsen3
  • 1Haemostasis Biology, Novo Nordisk A/S, Maaløv, Denmark
  • 2NovoSeven Research, Novo Nordisk A/S, Maaløv, Denmark
  • 3Global Development, Biopharmaceuticals Therapy Area,Novo Nordisk A/S, Bagsvaerd, Denmark
Further Information

Publication History

Publication Date:
18 July 2003 (online)


Following vessel wall injury, tissue factor (TF) is exposed and forms complexes with already activated factor VII (FVIIa) present in the circulating blood, thereby initiating the hemostatic process. After the first FXa is formed, the TF pathway inhibitor (TFPI) forms a complex with FXa, and a quaternary complex is formed, TF/FVIIa/ FXa/TFPI, which inhibits the first step of the hemostatic pathway. Recombinant activated FVII (rFVIIa) has been developed for use as a hemostatic agent (NovoNordisk A/S, Denmark). Active site-inactivated rFVIIa (rFVIIai) has also been prepared and was shown to have a faster association to and a slower dissociation from TF than rFVIIa, resulting in a lower calculated Kd of rFVIIai compared with rFVIIa. In various animal models rFVIIai has been demonstrated to prevent or diminish immediate thrombus formation at the site of vessel wall injury (athroplasty or other forms of mechanical injury) as well as the development of long-term intima thickening. The inflammatory response following endotoxin-induced sepsis was shown to decrease after administration of rFVIIai. Also, survival increased in the rFVIIai-treated animals in this study. In addition, ischemia-reperfusion injury was mitigated by rFVIIai. In a limited number of patients undergoing percutaneous transluminal coronary angioplasty (PTCA), rFVIIai was observed to allow PTCA to be performed at lower doses of heparin than what has been reported previously.


  • 1 Rapaport S I, Rao L V. Initiation and regulation of tissue factor-dependent blood coagulation.  Arterioscler Thromb . 1992;  12 1111-1121
  • 2 Rapaport S I, Rao L VM. The tissue factor pathway: how it has become a `prima ballerina.' Thromb Haemost .  1995;  74 7-17
  • 3 Hamada K, Kuratsu J, Saitoh Y, Takeshima H, Nishi T, Ushio Y. Expression of tissue factor correlates with grade of malignancy in human glioma.  Cancer . 1996;  77 1877-1883
  • 4 Seto S, Onodera H, Kaido T. Tissue factor expression in human colorectal carcinoma-correlation with hepatic metastasis and impact on prognosis.  Cancer . 2000;  88 295-301
  • 5 Ernofsson M, Siegbahn A. Platelet-derived growth factor-BB and monocyte chemotactic protein-1 induce human peripheral blood monocytes to express tissue factor.  Thromb Res . 1996;  83 307-320
  • 6 Rauch U, Bonderman D, Bohrmann B. Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor.  Blood . 2000;  96 170-175
  • 7 Lupu F, Westmuckett A D, Taylor Jr B F. Cell and tissue-specific expression of tissue factor pathway proteins in a baboon model of lethal E coli sepsis.   Blood . 2002;  100 496a
  • 8 Siggiqui F A, Desai H, Amirkhosravi A. Platelet microparticles from healthy donors contain tissue factor.  Blood . 2002;  100 1936
  • 9 Monroe D, Hoffman M, Roberts H R. Platelets and thrombin generation.  Arterioscler Thromb Vasc Biol . 2002;  22 1381-1389
  • 10 Monroe D M, Hoffman M, Oliver J A, Roberts H R. Platelet activity of high-dose factor VIIa is independent of tissue factor.  Br J Haematol . 1997;  99 542-547
  • 11 Hoffman M, Monroe D M, Oliver J A, Roberts H R. Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation.  Blood . 1995;  86 1794-1801
  • 12 Monroe D M, Hoffman M, Roberts H R. Transmission of a procoagulant signal from tissue factor-bearing cell to platelets.  Blood Coagul Fibrinolysis . 1996;  7 459-464
  • 13 Kjalke M, Oliver J A, Monroe D M. The effect of active site-inhibited factor VIIa on tissue factor-initiated coagulation using platelets before and after aspirin administration.  Thromb Haemost . 1997;  78 1202-1208
  • 14 Sorensen B B, Persson E, Freskgaard P O. Incorporation of an active site inhibitor in factor VIIa alters the affinity for tissue factor.  J Biol Chem . 1997;  272 11863-11868
  • 15 Hansen C B, Pyke C, Petersen L C, Rao L VM. Tissue factor-mediated endocytosis, recycling, and degradation of factor VIIa by a clathrin-independent mechanism not requiring the cytoplasmic domain of tissue factor.  Blood . 2001;  97 1712-1720
  • 16 Golino P, Ragni M, Cirillo P. Antithrombotic effects of recombinant human, active site-blocked factor VIIa in a rabbit model of recurrent arterial thrombosis.  Circ Res . 1998;  82 39-46
  • 17 Pendurthi U R, Rao L VM. Factor VIIa/tissue factor-induced signaling: a link between clotting and disease. In: Litwick G, ed. Vitamins and Hormones-Advances in Research and Applications San Diego, CA: Academic Press 2002: 323-355
  • 18 Rottingen J A, Enden T, Camerer E, Iversen J G, Prydz H. Binding of human factor VIIa to tissue factor induces cytosolic Ca2+ signals in J82 cells, transfected COS-1 cells, Madin-Darby canine kidney cells and in human endothelial cells induced to synthesize tissue factor.  J Biol Chem . 1995;  270 4650-4660
  • 19 Poulsen L K, Jacobsen N, Sorensen B B. Signal transduction via the mitogen-activated protein kinase pathway induced by binding of coagulation factor VIIa to tissue factor.  J Biol Chem . 1998;  273 6228-6232
  • 20 Versteeg H H, Hoedemaeker I, Diks S H. Factor VIIa/ tissue factor-induced signaling via activation of Src-like kinases, phosphatidylinositol 3-kinase, and Rac.  J Biol Chem . 2000;  275 28750-28756
  • 21 Taniguchi T, Kakkar A K, Tuddenham E GD, Williamson R CN, Lemoine N R. Enhanced expression of urokinase receptor induced through the tissue factor-factor VIIa pathway in human pancreatic cancer.  Cancer Res . 1998;  58 4461-4467
  • 22 Camerer E, Rottingen J A, Gjernes E. Coagulation factors VIIa and Xa induce cell signaling leading to up-regulation of the egr-1 gene.  J Biol Chem . 1999;  274 32225-32233
  • 23 Camerer E, Gjernes E, Wiiger M, Pringle S, Prydz H. Binding of factor VIIa to tissue factor on keratinocytes induces gene expression.  J Biol Chem . 2000;  275 6580-6585
  • 24 Pendurthi U R, Allen K E, Ezban M, Rao L VM. Factor VIIa and thrombin induce the expression of Cyr61 and connective tissue growth factor, extracellular matrix signaling proteins that could act as possible downstream mediators in factor VIIa center dot tissue factor-induced signal transduction.  J Biol Chem . 2000;  275 14632-14641
  • 25 Pendurthi U R, Alok D, Rao L V. Binding of factor VIIa to tissue factor induces alterations in gene expression in human fibroblast cells: up-regulation of poly(A) polymerase.  Proc Natl Acad Sci USA . 1997;  94 12598-12603
  • 26 Martin P. Wound healing-aiming for perfect skin regeneration.  Science . 1997;  276 75-81
  • 27 Osterud B, Bjorklid E. The tissue factor pathway in disseminated intravascular coagulation.  Semin Thromb Hemost . 2001;  27 605-617
  • 28 Taylor F B, Chang A, Ruf W. Lethal E coli septic shock is prevented by blocking tissue factor with monoclonal antibody.   Circ Shock . 1991;  33 127-134
  • 29 Gando S, Kameue T, Nanzaki S, Hayakawa T, Nakanishi Y. Participation of tissue factor and thrombin in posttraumatic systemic inflammatory syndrome.  Crit Care Med . 1997;  25 1820-1826
  • 30 Harker L A, Hanson S R, Kelly A B. Antithrombotic benefits and hemorrhagic risks of direct thrombin antagonists.  Thromb Haemost . 1995;  74 464-472
  • 31 Jang Y, Guzman L A, Lincoff A M. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model.  Circulation . 1995;  92 3041-3050
  • 32 Sanchez-Gomez A, Casani L, Vilahur G, Badimon L. FFR-rFVIIa inhibits thrombosis triggered by ruptured and eroded vessel wall.  Thromb Haemost . 2001;  Suppl July OC999
  • 33 Arnljots B, Ezban M, Hedner U. Prevention of experimental arterial thrombosis by topical administration of active site-inactivated factor VIIa.  J Vasc Surg . 1997;  25 341-346
  • 34 Holst J, Kristensen A T, Kristensen H I, Ezban M, Hedner U. Local application of recombinant active-site inhibited human clotting factor VIIa reduces thrombus weight and improves patency in a rabbit venous thrombosis model.  Eur J Vasc Endovasc Surg . 1998;  15 515-520
  • 35 Herskowitz A, Choi S, Ansari A A, Wesselingh S. Cytokine mRNA expression in postischemic/reperfused myocardium.  Am J Pathol . 1995;  146 419-428
  • 36 Kranzhofer R, Clinton S K, Ishii K, Coughlin S R, Fenton I I, Libby P. Thrombin potently stimulates cytokine production in human vascular smooth muscle cells but not in mononuclear phagocytes.  Circ Res . 1996;  79 286-294
  • 37 Ma X L, Lefer D J, Lefer A M, Rothlein R. Coronary endothelial and cardiac protective effects of a monoclonal antibody to intercellular adhesion molecule-1 in myocardial ischemia and reperfusion.  Circulation . 1992;  86 937-946
  • 38 Golino P, Ragni M, Cirillo P. Effects of recombinant active site-blocked activated factor VII in rabbit models of carotid stenosis and myocardial infarction.  Blood Coagul Fibrinolysis . 2000;  11 S149-S158
  • 39 Erlich J H, Boyle E M, Labriola J. Inhibition of the tissue factor-thrombin pathway limits infarct size after myocardial ischemia-reperfusion injury by reducing inflammation.  Am J Pathol . 2000;  157 1849-1862
  • 40 Osterholm C, Qi Z Q, Ekberg J. Initial inhibition of tissue factor signalling reduces chronic vascular changes in isogenic rat aortic transplants.  Am J Transplant . 2001;  1 29-37
  • 41 Taylor F B. Role of tissue factor and factor VIIa in the coagulant and inflammatory response to LD100 Escherichia coli in the baboon.  Haemostasis . 1996;  26 (suppl 1) 83-91
  • 42 Creasey A A, Chang A C, Feigen L, Wün T C, Taylor F B, Hinshaw L B. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock.  J Clin Invest . 1993;  91 2850-2856
  • 43 Taylor F B, Chang A C, Peer G, Li A, Ezban M, Hedner U. Active site inhibited factor VIIa (DEGR VIIa) attenuates the coagulant and interleukin-6 and -8, but not tumor necrosis factor, responses of the baboon to LD100 Escherichia coli Blood .  1998;  91 1609-1615
  • 44 Erhardtsen E, Nilsson P, Johannessen M, Thomsen M S. Pharmacokinetics and safety of FFR-rFVIIa after single doses in healthy subjects.  J Clin Pharmacol . 2001;  41 880-885
  • 45 Lincoff A M. First clinical investigation of a tissue factor inhibitor administered during percutaneous coronary revascularizatoin: a randomized, double-blinded, dose-escalation trial-assessing safety and efficacy of FFR-rFVIIa in PTCA (ASIS) trial. Presentation of Late Breaking Clinical Trials in Interventional Cardiology at ACCIS 2000, March 2000
  • 46 Lev E I, Marmur J D, Zdravkovic M. Antithrombotic effect of tissue factor inhibition by inactivated factor VIIa: an ex vivo human study.  Arterioscler Thromb Vasc Biol . 2002;  22 1036-1041
  • 47 Jilma B, Marsik C, Mayr F. Pharmacodynamics of active site-inhibited factor VIIa in endotoxin-induced coagulation in humans.  Clin Pharmacol Ther . 2002;  72 403-410